VM 26 and VP 16–213: A comparative analysis
Abstract
VM 26 and VP 16–213 are epipodophyllotoxin analogs. This paper presents a comparative analysis of their experimental and clinical features but fails to disclose any significant difference between these drugs. Similar studies with other classes of compounds might help to define some rationale for the development of analogous cytotoxic agents. Cancer 40:334–342, 1977.Keywords
This publication has 29 references indexed in Scilit:
- Combination chemotherapy with 4′Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside), VP 16–213 (NSC 141540) in L1210 Leukemia1976
- Evaluation of VP-16 and the Combination of Adriamycin and Vincristine in Advanced Breast CancerOncology, 1976
- Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.BMJ, 1975
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesEuropean Journal of Cancer (1965), 1975
- PTG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975
- EPEG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975
- Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia—Haematosarcoma and Solid TumoursBMJ, 1973
- Clinical Screening of Epipodophyllotoxin VM26 in Malignant Lymphomas and Solid TumoursBMJ, 1972
- Human anticancer effect of podophyllum derivatives (SPG and SPI): a preliminary report.British Journal of Cancer, 1967
- THE ACTION OF PODOPHYLLIN AND ITS FRACTIONS ON MARINE EGGSAnnals of the New York Academy of Sciences, 1951